AKT2 and Hyperglycemia: However, despite this relatively improved benefit of combining MK2206 and gefitinib in EGFR M+ cells, preclinical data using mouse models has shown that combined inhibition of both AKT1 and AKT2 can result in insulin resistance as well as hyperglycaemia and hyperinsulinaemia [37].